Drug marketing costs double R&D

Every self-respecting pharma exec will tell you: R&D is the industry's peculiar burden, the chief reason why brand-name drugs are so expensive. But the average Joe or Jane consumer thinks that's, er, a lot of bunk. It's marketing that drives the costs of their meds ever upward.

Now, a couple of academics have the figures. After combing through market research, they found that pharma spent $57.5 billion on marketing in 2004--almost twice the $31.5 billion spent on research that year, according to the National Science Foundation. And the research numbers include public funding, not just company expenses.

The data "confirms the public image of a marketing-driven industry," the study authors wrote. It also shows that the industry needs to be redirected toward research and away from brand-building, they wrote. Just how might that redirection happen? They didn't say.

- see this release release
-get the journal article from PLoS Medicine

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.